Sensus Healthcare, Inc.
SRTS
Rank in Stocks
#22545
Sensus Healthcare, Inc. operates as a medical technology enterprise,... Sensus Healthcare, Inc. operates as a medical technology enterprise, manufacturing and distributing radiation therapy apparatuses to medical institutions across the globe. The company's portfolio leverages superficial radiation therapy (SRT), a cutting-edge low-energy X-ray methodology. Their product line features the SRT-100, a photon X-ray system for low-energy superficial radiotherapy. This device presents a non-surgical alternative for patients dealing with non-melanoma skin cancers, including basal cell and squamous cell carcinomas, alongside other dermatological issues like keloids. Another key offering is the SRT-100 Vision, which incorporates a specialized SRT treatment planning application. This application seamlessly integrates an embedded high-frequency ultrasound imaging module, tools for volumetric tumor analysis, beam margin delineation, and dosimetry parameter configuration. In addition, Sensus Healthcare provides the SRT-100 Plus, the Sentinel service program to ensure system protection for its clients, and options for in-office laser rentals. They also supply various consumable items, such as replacement lead shielding, disposable radiation safety gear like aprons and eye shields, ultrasound probe film, and single-use applicator tips designed to treat lesions of different sizes and on various body areas. Founded in 2010, Sensus Healthcare, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Share Price
$3.18
Last synced: 2026-11-09
Market Cap
$52.35M
Change (1 day)
11.19%
Change (1 year)
-24.47%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Sensus Healthcare, Inc. (SRTS)
Category
Healthcare
Operating Margin for Sensus Healthcare, Inc. (SRTS)
Operating Margin as of November 2026 TTM: -75.72%
According to Sensus Healthcare, Inc.'s latest financial reports, its current operating margin (TTM) is -75.72%. At the end of 2025 the company had an operating margin of -37.50%.
Operating Margin history for Sensus Healthcare, Inc. from 2012 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -75.72% | 101.92% |
| 2025 | -37.50% | -293.80% |
| 2024 | 19.35% | -1,332.48% |
| 2023 | -1.57% | -104.71% |
| 2022 | 33.30% | 118.50% |
| 2021 | 15.24% | -117.73% |
| 2020 | -85.98% | 1,090.86% |
| 2019 | -7.22% | -4.87% |
| 2018 | -7.59% | -57.97% |
| 2017 | -18.06% | 637.14% |
| 2016 | -2.45% | 13.95% |
| 2015 | -2.15% | -96.61% |
| 2014 | -63.34% | -5,334.71% |
| 2013 | 1.21% | 0.00% |
| 2012 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 15.24% | -100.20% |
US
|
|
| 18.08% | -100.24% |
IE
|
|
| 21.25% | -100.28% |
US
|
|
| 21.05% | -100.28% |
US
|
|
| 28.09% | -100.37% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Sensus Healthcare, Inc.'s operating margin
What is Sensus Healthcare, Inc.'s operating margin?
Sensus Healthcare, Inc.'s operating margin is -75.72%, as of Nov 2026.
What was Sensus Healthcare, Inc.'s operating margin in 2025?
In 2025, Sensus Healthcare, Inc.'s operating margin was -37.50%, compared with 19.35% in 2024.
How has Sensus Healthcare, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Sensus Healthcare, Inc.'s operating margin was highest in 2022 (33.30%) and lowest in 2020 (-85.98%).
How does Sensus Healthcare, Inc.'s operating margin compare with similar companies?
Sensus Healthcare, Inc.'s operating margin (-75.72%) is lower than that of all 5 similar companies listed above. The highest among them is Edwards Lifesciences Corporation, with 28.09%.